Skip to main content
Dr Jie Yu
Cardiologist / Clinician-researcher
LinkedIn
ORCID
Back to team

Dr Jie Yu

PhD, MD, FRACP

Jie is a cardiologist and clinician-researcher with more than 15 years of clinical and academic experience across China and Australia. She completed her medical degree and PhD at Peking University, and later worked as a Consultant and Associate Professor at Peking University Third Hospital.

She relocated to Australia in 2018 to pursue cardiovascular research at the George Institute for Global Health, where she held leadership roles in major international studies, including Chair of the Endpoint Adjudication Committee for the Salt Substitute and Stroke Study (NCT02092090) and Principal Investigator for the first salt-substitute trial in rural India (Salt Substitute in India Study, NCT03909659). She later returned to clinical cardiology in Australia and undertook further training in heart failure, cardiac imaging and cardio-oncology. She is currently a Conjoint Senior Lecturer at the University of Newcastle and previously served as Co-Deputy Director of the Heart and Stroke Program at the Hunter Medical Research Institute.

A central theme of her work is delivering evidence-based, patient-centred care more effectively, particularly for people with complex conditions and those living in regional and rural communities. Her recent research reflects growing interests in telehealth models of care, cancer survivorship and precision medicine in cardiovascular disease. Her overall goal is to integrate clinical excellence, research impact and health equity to improve cardiovascular outcomes, and she is committed to teaching and mentoring junior doctors and emerging clinician-researchers.

Research interests

  • Cardio-oncology (the overlap between heart disease and cancer care)
  • Heart failure
  • Hypertension
  • Preventive cardiology
  • Health service innovation

Highlights

  • 70 peer-reviewed publications
  • First-author work in JAMA, Cardiovascular Research, ESC Heart Failure and Hypertension
  • Co-authorship in the New England Journal of Medicine and Circulation

Current projects

  • Principal Investigator, TELE-CO: a physician-led telehealth cardio-oncology service for patients in regional and rural New South Wales
  • Co-Investigator, I-HALO: improving heart failure outcomes
  • BACS study: broadening access to cardiovascular services in regional, rural and remote settings, including handheld echocardiography
  • HOPES trial: how genetics may help guide more personalised treatment for hypertension
  1. Bennetts JD, Robson C, Weismantel-Savage A, Mani J, Yu J, Robson L, Collins NJ, Williams TD, Sverdlov AL, Ngo DTM. Evaluation of a Nurse-Pharmacist Post-Discharge Telehealth Model of Care for People With Heart Failure. Heart Lung Circ. 2026 Mar 19:S1443-9506(26)00055-7.
  2. Bennetts JD, Mahmud A, Yu J, Ngo DTM, Sverdlov AL. From signal to care: Artificial intelligence in Cardio-oncology. Trends Cardiovasc Med. 2026 Mar 25:S1050-1738(26)00042-3.
  3. Butel-Simoes LE, Albayati A, Yu J, Quirk T, Sritharan S, French M, Bennetts JD, Ngo DTM, Sverdlov AL. Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding. J Thromb Thrombolysis. 2026 Feb;59(2):393-410.
  4. Nguyen TN, Yu J, Perkovic V, Jardine M, Mahaffey KW, Chow CK, Arnott C, Lindley RI. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025 Jun;73(6):1787-1796.
  5. Nguyen TN, Yu J, Perkovic V, Arnott C, Lindley RI. REPLY: The Assessment Approach of Frailty May Influence Its Prognostic Impact Amidst Clinical Trials. J Am Geriatr Soc. 2025 Nov;73(11):3620-3621.
  6. Yang H, Yang L, Jardine MJ, Arnott C, Neuen BL, Xu K, Zhao X, Qian D, Cui B, Qiu Y, Huang Y, Yu J, Wang J, Yu S, Tan H, Huang L, Li JW, Jin J. The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: a propensity-matched study. Eur J Med Res. 2024 Dec 24;29(1):621.
  7. Wang X, Shaw JE, Yu J, Jennings G, Stavreski B, Magliano D, Gill TK, Adams R, Rodgers A, Woodward M, Schlaich MP, Singleton R, Zhou B, Schutte AE. Prevalence, awareness, treatment, and control rates of hypertension in the general population of Australia: a systematic review and meta-analysis. J Hypertens. 2025 Feb 1;43(2):185-190
  8. Zeng Q, Chang W, Zhang R, Fan H, Dou Z, Liu A, Yu J, Zhou B. Association of Cancer with Heart Failure and the Prognostic Value of NT-proBNP in Cancer Patients: Findings from the NHANES (1999-2018). Curr Oncol. 2024 Aug 26;31(9):4927-4939. (Equal corresponding author)
  9. Yu J, Houston L, Gianacas C, Lee V, Fletcher RA, Chen AX, Arnott C. Knowledge, attitudes, and behaviors related to dietary salt intake and the acceptability of salt substitute among the Australian culturally and linguistically diverse community: An online survey. J Clin Hypertens (Greenwich). 2024 May;26(5):543-552.
  10. Zhou Z, You S, Sakamoto Y, Xu Y, Ding S, Xu W, Li W, Yu J, Wang Y, Harris K, Delcourt C, Reeves MJ, Lindley RI, Parsons MW, Woodward M, Anderson C, Du X, Pu J, Wardlaw JM, Carcel C. Covert Cerebrovascular Changes in People With Heart Disease: A Systematic Review and Meta-Analysis. Neurology. 2024 Apr 23;102(8): e209204.
  11. Yu J, Arnott C, Li Q, Di Tanna GL, Tian M, Huang L, Yin X, Zhang X, Pearson SA, Labarthe DR, Elliott P, Yan LL, Zhou B, Wu Y, Neal B. Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes. Hypertension. 2024 May;81(5):1031-1040.
  12. Huang L, Li Q, Wu JH, Tian M, Yin X, Yu J, Liu Y, Zhang X, Wu Y, Paige E, Trieu K, Marklund M, Rodgers A, Neal B. The contribution of sodium reduction and potassium increase to the blood pressure lowering observed in the Salt Substitute and Stroke Study. J Hum Hypertens. 2024 Apr;38(4):298-306.
  13. Lee VYJ, Houston L, Perkovic A, Barraclough JY, Sweeting A, Yu J, Fletcher RA, Arnott C. The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Heart Lung Circ. 2024 Feb 5:S1443-9506(23)04460-8.
  14. Jain SS, Yu J, Arnott C, Neal B, Perkovic V, Neuen BL, Jardine M, Mahaffey KW. Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial. Int J Cardiol. 2024 Jan 15;395:131444.
  15. Yu J, Sweeting AN, Gianacas C, Houston L, Lee V, Fletcher RA, Perkovic V, Li Q, Neuen BL, Berwanger O, Heerspink HJL, de Zeeuw D, Arnott C. The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2023 Dec;25(12):3724-3735.
  16. Charytan DM, Mahaffey KW, Jardine MJ, Cannon CP, Neal B, Lambers Heerspink HJ, Agarwal R, Bakris GL, de Zeeuw D, Levin A, Pollock C, Zhang H, Zinman B, Rosenthal N, Perkovic V, Di Tanna GL, Yu J, Rogers K, Arnott C, Wheeler DC. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 Jun;11(3):e003270.
  17. Yin X, Paige E, Tian M, Li Q, Huang L, Yu J, Rodgers A, Elliott P, Wu Y, Neal B. The Proportion of Dietary Salt Replaced With Potassium-Enriched Salt in the SSaSS: Implications for Scale-Up. Hypertension. 2023 May;80(5):956-965.
  18. Zhang S, Li J, Huang Y, Yu J, Pan XF. Editorial: New mechanisms and drugs for the treatment of cardiovascular disease with diabetes. Front Cardiovasc Med. 2023 Feb 20;10:1144858. doi: 10.3389/fcvm.2023.1144858.
  19. Thout SR, Yu J, Santos JA, Hameed M, Coyle DH. Dietary intakes of hypertensive patients in rural India: Secondary outcomes of a randomised, double-blind, controlled trial. Dialogues Health. 2023 Feb 3;2:100109. (Equal First author)
  20. Zhang X, Padhi A, Wei T, Xiong S, Yu J, Ye P, Tian W, Sun H, Peiris D, Praveen D, Tian M. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Glob Health. 2022 Sep;7(9):e008880.
  21. Nunes JC, Yu J, Arnott C, Jardine MJ, Perkovic V, Mahaffey KW. Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program. Diabetes Obes Metab. 2022 Dec;24(12):2459-2464.
  22. Yin, X., Rodgers, A., Perkovic, A., Huang, L., Li, K.-C., Yu, J., et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta- analysis. Heart. 2022 Sep 26;108(20):1608-1615.
  23. Marklund M, Tullu F, Raj Thout S, Yu J, Brady T, Appel LJ, Neal B, Wu JHY, Gupta R. Estimated Benefits and Risks of Using a Reduced-Sodium, Potassium-Enriched Salt Substitute in India: A Modelling Study. Hypertension. 2022 Oct;79(10):2188-2198.
  24. Li C, Yu J, Hockham C, Perkovic V, Neuen BL, Badve SV, Houston L, Lee VY, Barraclough JY, Fletcher RA, Mahaffey KW, Heerspink HJL, Cannon CP, Neal B, Arnott C. Canagliflozin and Atrial Fibrillation in Type 2 Diabetes Mellitus: A secondary analysis from the CANVAS Program and CREDENCE trials and meta-analysis. Diabetes Obes Metab. 2022 Oct;24(10):1927-1938. (Equal First author and corresponding author).
  25. Bernabe-Ortiz A, Trieu K, Markland M, Hy Wu J, Saavedra-Garcia L, Hart AC, Yu J, Thout SR, Miranda JJ, Webster J. The potential scalability of salt substitutes as an intervention to lower population sodium levels. Salud Publica Mex. 2022 Jun 13;64:S6-S13.
  26. Li KC, Huang L, Tian M, Di Tanna GL, Yu J, Zhang X, Yin X, Liu Y, Hao Z, Zhou B, Feng X, Li Z, Zhang J, Sun J, Zhang Y, Zhao Y, Zhang R, Yu Y, Li N, Yan LL, Labarthe DR, Elliott P, Wu Y, Neal B, Lung T, Si L. Cost-effectiveness of a Household Salt Substitution Intervention: Findings From 20,995 Participants of the Salt Substitute and Stroke Study (SSaSS). Circulation. 2022 May 17;145(20):1534-1541.
  27. Zhai Q, Duan J, Yu J, Zhang H, He X, Ma Q. Letter to the Editor: From Target Temperature Management Trial 1 to Trial 2: Therapeutic Hypothermia for Cardiac Arrest Discredited? Ther Hypothermia Temp Manag. 2022 Feb 28.
  28. Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, Cannon CP, Mahaffey KW, Schutte AE, Neal B, Arnott C. Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials. Diabetes Obes Metab. 2022 Jun;24(6):1072-1083. (Equal First author).
  29. Charytan DM, Yu J, Jardine MJ, Cannon CP, Agarwal R, Bakris G, Greene T, Levin A, Pollock C, Powe NR, Arnott C, Mahaffey KW; CREDENCE study investigators. Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 Mar;17(3):361-373.
  30. Yu J, Li J, Leaver PJ, Arnott C, Huffman MD, Udell JA, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Rosenthal N, Neal B, Figtree GA. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS program and CREDENCE trial. Cardiovasc Res. 2022 Mar 16;118(4):1103-1114.
  31. Duan J, Zhai Q, Shi Y, Ge H, Zheng K, Du L, Duan B, Yu J and Ma Q (2022). Optimal Time of Collapse to Return of Spontaneous Circulation to Apply Targeted Temperature Management for Cardiac Arrest: A Bayesian Network Meta-Analysis. Front Cardiovasc Med. 2022 Jan 7; 8:784917. (Corresponding author).
  32. Brown LJ, Meredith T, Yu J, Patel A, Neal B, Arnott C, Lim E. Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers (Basel). 2021 Nov 3;13(21):5527.
  33. Barraclough, J.Y., Patel, S., Yu, J., Neal, B., Arnott, C. The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms. Cells. 2021 Oct 9;10(10):2699.
  34. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, Zhang J, Tian M, Huang L, Li Z, Yu Y, Zhao Y, Zhou B, Sun J, Liu Y, Yin X, Hao Z, Yu J, Li KC, Zhang X, Duan P, Wang F, Ma B, Shi W, Di Tanna GL, Stepien S, Shan S, Pearson SA, Li N, Yan LL, Labarthe D, Elliott P. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021 Sep 16;385(12):1067-1077.
  35. Li KC, Tian M, Neal B, Huang L, Yu J, Liu Y, Yin X, Zhang X, Wu Y, Li N, Elliott P, Yan L, Labarthe D, Hao Z, Shi J, Feng X, Zhang J, Zhang Y, Zhang R, Zhou B, Li Z, Sun J, Zhao Y, Yu Y, Si L, Lung T. Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS). BMJ Open. 2021 Jul 20;11(7): e045929.
  36. Barraclough JY, Harmer JA, Yu J, Figtree GA, Arnott C. Why Are We Forgetting Patients with Peripheral Arterial Disease? Heart Lung Circ. 2021 Jul;30(7):939-942.
  37. Yu J, Thout SR, Li Q, Tian M, Marklund M, Arnott C, Huffman MD, Praveen D, Johnson C, Huang L, Pettigrew S, Neal B, Wu JHY. Effects of a reduced-sodium added-potassium salt substitute on blood pressure in rural Indian hypertensive patients: a randomized, double blind, controlled trial. Am J Clin Nutr. 2021 Jul 1;114(1):185-193.
  38. Khan SS, Huffman MD, Harrington K, Baldridge AS, Yu J, Neal B, Arnott C, Shah SJ. Association of baseline diuretic use with cardiovascular outcomes in patients with heart failure with preserved ejection fraction: A secondary analysis from TOPCAT. J Card Fail. 2021 Jul;27(7):816-818.
  39. Yu J, Arnott C, Neuen BL, Heersprink HL, Mahaffey KW, Cannon CP, Khan SS, Baldridge AS, Shah SJ, Huang Y, Li C, Figtree GA, Perkovic V, Jardine MJ, Neal B, Huffman MD. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program. ESC Heart Fail. 2021 Apr;8(2):1482-1493.
  40. Yu J, Zhou Z, Mahaffey KW, Matthews DR, Neuen BL, Heerspink HJL, Jardine MJ, Li J, Perkovic V, Neal B, Arnott C. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. Int J Cardiol. 2021 Feb 1; 324:165-172.
  41. Li C, Zhou Z, Neuen BL, Yu J, Huang Y, Young T, Li J, Li L, Perkovic V, Jardine MJ, Keay L, Markoulli M, Rosenthal N, Capuano G, Yavin Y, Neal B, Arnott C. Sodium-glucose co- transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2021 Jan;23(1):252-257.
  42. Huang L, Yu J, Neal B, Liu Y, Yin X, Hao Z, Wu Y, Yan LL, Wu JH, Joshi R, Shi J, Feng X, Zhang J, Zhang Y, Zhang R, Zhou B, Li Z, Sun J, Zhao Y, Yu Y, Pearson SA, Chen Z, Tian M. Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS). J Epidemiol Community Health. 2020 Dec 7:jech-2020-214063. (Equal First author).
  43. Thout SR, Yu J, Tian M, Huffman MD, Arnott C, Li Q, Devarsetty P, Johnson C, Pettigrew S, Neal B, Wu JHY. Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial. J Clin Hypertens (Greenwich). 2020 Aug;22(8):1504-1512. (Equal First author).
  44. Huang L, Tian M, Yu J, Li Q, Liu Y, Yin X, Wu JH, Marklund M, Wu Y, Li N, Elliott P, Yan LL, Labarthe DR, Hao Z, Shi J, Feng X, Zhang J, Zhang Y, Zhang R, Zhou B, Li Z, Sun J, Zhao Y, Yu Y, Neal B. Interim effects of salt substitution on urinary electrolytes and blood pressure in the China Salt Substitute and Stroke Study (SSaSS). Am Heart J. 2020 Mar; 221:136-145.
  45. Feng B, Song X, Dan M, Yu J, Wang Q, Shu M, Xu H, Wang T, Chen J, Zhang Y, Zhao Q, Wu R, Liu S, Yu JZ, Wang T, Huang W. High level of source-specific particulate matter air pollution associated with cardiac arrhythmias. Sci Total Environ. 2019 Mar 20 ;657 :1285-1293.
  46. Zhou Z, Yu J, Carcel C, Delcourt C, Shan J, Lindley RI, Neal B, Anderson CS, Hackett ML. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open. 2018 May 14;8(5):e019672. (Equal First author).
  47. Yu J, Zhou Z, McEvoy RD, Anderson CS, Rodgers A, Perkovic V, Neal B. Association of Positive Airway Pressure with Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2017 Jul 11;318(2):156-166.
  48. Yu J, Han JL, Wang GS, Guo LJ, Gao W. Serum total bilirubin levels and disease severity in patients with stable coronary artery disease. Herz. 2017 Jun;42(4):403-410.
  49. Yu J, Zhou B, Yu H, Han J, Cui M, Zhang F, Wang G, Guo L, Gao W. Association between plasma ADAMTS-7 levels and severity of disease in patients with stable obstructive coronary artery disease. Medicine (Baltimore). 2016 Nov;95(48):e5523.
  50. Yu J, Han J, Mao J, Guo L, Gao W. Association between serum uric acid level and the severity of coronary artery disease in patients with obstructive coronary artery disease. Chin Med J (Engl). 2014;127(6):1039-45.
  51. Yu J, Han JL, He LY, Feng XH, Li WH, Mao JM, Gao W, Wang G. Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes. J Geriatr Cardiol. 2013 Jun;10(2):159-64.
  52. Wang G, He L, Liu J, Yu J, Feng X, Li F, Hao Y, Mao J, Hong T, Chen AF, Wang X. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther. 2013 Jun;31(3):161-7.
  53. Yu J, Zhang Z, Li Z, Feng X, He L, Liu S, Mao J, Wang G, Wang X. Peroxisome proliferator- activated receptor-gamma (PPAR gamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res. 2010 Jan- Feb;38(1):86-94.
  54. He L, Zeng H, Li F, Feng J, Liu S, Liu J, Yu J, Mao J, Hong T, Chen AF, Wang X, Wang G. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with Hyperhomocysteinemia. Am J Physiol Endocrinol Metab. 2010 Dec;299(6):E1061-5.
  55. Wang G, Zhang Z, Yu J, Zhang F, He L, Wei J, Mao J, Wang X. Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease. PPAR Res. 2008; 2008:548178.
  56. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007 Oct;56(10):1396-401.
  57. Zhao Menglin, Zu Lingyun, Niu Jie, Gao Wei, Yu Jie. One acute myocardial infarction with renal infarction. Chin J Intervent Cardiol. 2018, 26 (7):412-413. (Corresponding author). Chinese.
  58. Menglin Zhao, Jie Yu, Lingyun Zu. Advances in research of high-flow nasal cannula oxygen therapy for heart failure. Chinese Circulation Journal. 2018, 33(4):407-410.43. Chinese.
  59. Chen Shaomin, Zhao Wei, Chen Baoxia, Yu Jie, Huang Jing, Cui Ming, Gao Wei. Sketching from the consultations with cardiologists: an insight into the direction of the continuing medical education reform. Chin J Clinicians (Electronic Edition). 2017,11 (1):172-175. Chinese.
  60. Zhao Menglin, Yu Jie, Zu lingyun. Advances in the diagnosis and treatment of hypertrophic cardiomyopathy. Chin J Cardiovasc Med. 2017, 22 (5):364-368. Chinese.
  61. Yu J, Wan F, Xie JY, Wu S, Cui ZQ, Xu M, Zhang Z, Gao W. Role of EuroSCORE and SinoSCORE in prediction of early postoperative quality of life in patients after coronary artery bypass surgery. Beijing Da Xue Xue Bao Yi Xue Ban. 2015 Oct 18;47(5):769-73. Chinese.
  62. YU Jie, Wang Fangfang, Huang Jing, Feng Xinheng, Chen Baoxia, Han Qingfeng, Gao Wei. Evaluation of Case-based Learning Model on Cardiovascular Medicine Clinical Probation Period. Continuing Medical Education. 2015,29 (3):27-29. Chinese.
  63. Qiu Yuan, Nie Dan, Yu Jie. Non lipid regulating effect of statins. Chin J Clinicians (Electronic Edition). 2015,9 (22):4172-4175. (Corresponding author). Chinese.
  64. Yu J, He LY, Han JL, Li ZP, Feng XH, Gao W. Correlation of low density lipoprotein cholesterol with coronary flow reserve in patients with type 2 diabetes. Beijing Da Xue Xue Bao Yi Xue Ban. 2014 Feb 18;46(1):155-9. Chinese.
  65. YU Jie, Huang Jing, Feng Xinheng, Zeng Hui, Gao Wei. Some Thoughts on Medical Students Doctor-Patients Communication Capacity Building. Continuing Medical Education. 2014,28 (8):107-108. Chinese.
  66. YU Jie, Huang Jing, Feng Xinheng, Zeng Hui, Gao Wei. Exploration and Practice of case teaching method in the teaching for eight-year medical students in the department of cardiology. Continuing Medical Education. 2014,28 (9), 88-89. Chinese.
  67. YU Jie, Han Jiangli, Huang Jing, Feng Xinheng, Gao Wei. Effect of social practice on holistic education philosophy for medical graduate students. Chinese Journal Medical Education Research. 2014,13 (12):12-14. Chinese.
  68. Hao YT, Zhang YZ, Mao JM, He LY, Yu J, Wang C, Feng JL, Liu JB, Feng XH, Hong TP, Wang G. Correlation of large artery stiffness and coronary flow velocity reserve. Zhonghua Yi Xue Za Zhi. 2012 Mar 13;92 (10):685-8. Chinese.
  69. ZHANG Su-min, YU Jie, WANG Guang, ZENG Hui, MAO Jie-ming. Effect of simvastatin on the large artery stiffness in Hyperlipidemia patients without coronary artery disease. Chin J Clin Pharmacol. 2012;28 (3): 163-164. Chinese.
  70. Y Nie, Chen BX, Feng XH, Li ZP, Yu Y, Yu J, Xu M, Gao W. Evaluation of arterial elasticity in initial hypertension by pulse wave velocity and wave intensity technique. Zhonghua Yi Xue Za Zhi. 2012 Mar 20;92 (11):764-7. Chinese.
  71. WANG Guang, HE Li-yun, YU Jie, GAO Xia, MIAO Li, WANG Chen, LI Wei-hong, AN Hui- jie, XU Yuan. Research on improvement of coronary artery endothelial function by PPAR-α agonist in patients with hypertriglyceridemia. Chinese Journal of Clinicians (Electronic Edition). 2012,6 (24):8020-8023. Chinese.
  72. Yu Jie, Han Jiangli, Wang Guisong, Guo Lijun, Gao Wei. Antiphospholipid syndrome with acute myocardial infarction. Chinese Journal of Cardiology. 2011,39 (1):84. Chinese.
  73. ZHANG Su-min, WANG Guang, ZENG Hui, LIU Jin-bo, YU Jie, MI Lin, MAO Jie-ming. Effects of simvastatin on the endothelial function in hyperlipidaemia patients without coronary artery disease. Shandong Medicine. 2010,50 (36):7-9. Chinese.
  74. Yu Jie, Wang Guang, Zhang Yuan, Zhang Yongzhen, Li Hanyan, Guo Lijun, Gao Wei, Han Jiangli. Intermittent pain with pharynx tightness/sweating. Shandong Medicine. 2010,50 (24):116-117. Chinese.
  75. HE Li-yun, WANG Guang, LIU Shan, YU Jie, MAO Jie-ming. The relationship between arteriaI stiffness and serum Ievels of high-sensitivity C-reactive protein in patients with hypertriglyceridemia. Shandong Medicine. 2009,49 (4):7-9. Chinese.
  76. Yu Jie, Mao Jieming, Wang Guang. Changes in plasma monocyte chemoattractant protein-in patients with acute coronary syndrome and patients with restenosis after angioplasty. Journal of Clinical Rehabilitative Tissue Engineering Research. 2007,11 (4):653-656. Chinese.
  77. Yu Jie, Mao Jieming, Zhang Fuchun, Wang Guang. Peroxisome Proliferator Activated Receptor-λ Agonists Improves Arterial Stiffness in Type 2 Diabetic Patients With Coronary Artery Disease. Chinese Circulation Journal. 2007,22 (6):418-422. Chinese.
  78. Xiao H, Yu J, Li ZP. Isoproterenol regulates lipopolysaccharide-induced tumor necrosis factor-alpha and interleukin-6 production in monocytes from essential hypertensive patients. Beijing Da Xue Xue Bao Yi Xue Ban. 2007 Dec 18;39(6):581-6. Chinese.